Protocol Number: 07-H-0091

Title:

WTI Peptide Vaccination for Patients with High Risk Hematological Malignancies

Number:

07-H-0091

Summary:

This study will determine the safety and effectiveness of an experimental vaccine in controlling the abnormal growth of cells in patients with myelodysplastic syndrome (MDS, also known as myelodysplasia), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myeloid leukemia (CML). It will test whether the vaccine can increase the number of immune cells responding to the cancer and thereby slow progression of the illness, improve blood counts, reduce the need for transfusions of blood and platelets, or even achieve a disease remission. The vaccine contains part of a protein that is produced in large amounts by cells of patients with these cancers and an added substance called Montanide that helps the immune system respond to the vaccine. Sargramostim, another substances that boosts the immune response, is also given.

Patients 18 to 85 years of age with MDS, AML, ALL or CML may be eligible for this study. Candidates are screened with a medical history, physical examination, blood tests, chest x-ray and bone marrow biopsy. Women of childbearing age also have a pregnancy test.

Participants undergo the following:

-Chemotherapy entering the study.

-Leukapheresis to collect large amounts of white blood cells for infusion before vaccine administration.

-Participants may need placement of a central line (plastic tube, or catheter) in the upper part of the chest to be used for giving chemotherapy, blood or platelet transfusions, antibiotics and white blood cells, and for collecting blood samples.

-Weekly vaccine injections for nine weeks, given in the upper arm, upper leg or abdomen.

-Sargramostim injections following each vaccination.

-Standard of care treatment for MDS, AML, ALL or CML, which may include blood or platelet transfusions, growth factors, and drugs to control underlying disease and potential side effects of the vaccine.

-Weekly safety monitoring, including vital signs check, brief health assessment, blood tests and observation after the vaccination, on the day of each vaccination.

-Follow-up evaluations with blood tests and chest x-ray 3 weeks after the last vaccine dose and with blood tests and bone marrow biopsy 7 weeks after the last vaccine dose.

Sponsoring Institute:

National Heart, Lung and Blood Institute (NHLBI)

Recruitment Detail

Type: Participants currently recruited/enrolled

Gender: Male & Female

Referral Letter Required: Yes

Population Exclusion(s): Children

Eligibility Criteria:

INCLUSION CRITERIA:

1. Diagnosed with

refractory anemia with excess of blasts (MDS-RAEB).

or

refractory anemia with excess of blasts in transformation (MDS-RAEBt).

or

secondary acute myelogenous leukemia (AML).

or

relapsed or refractory acute or chronic myelogenous leukemias (AML or CML).

or

relapsed or refractory acute lymphoblastic leukemia (high risk ALL).

or

acute lymphoblastic leukemia (ALL) in complete remission.

or

chronic myelomonocytic leukemia (CMML).

2. Unsuitable for stem cell transplantation (age over sixty or unavailability of a fully-matched donor).

or

made an informed decision not to undergo the transplant procedure.

or

relapsed AML, CML, MDS or ALL post stem cell transplantation (SCT).

3. HLA-A0201 positive.

4. Ages 18 - 85 years.

5. Off all lymphoablative chemotherapeutic agents.

6. All subjects (men and women) must agree to practice abstinence or effective contraception during the study period.

Inclusion Criteria Donor (for post transplant subjects without available DLI cells):

1. Related donor, HLA identical (6/6) with recipient.

2. Age greater than or equal to 18 or less than or equal to 80 years old.

3. Ability to comprehend the investigational nature of the study and provide informed consent.

EXCLUSION CRITERIA:

1. HIV positive (HIV-infected patients are immune-compromised and it is unlikely that these patients will be capable of mounting an immune response to the vaccine).

2. Treatment with systemic corticosteroids within 7 days prior to study entry.

3. Low bone marrow reserves (less than 20 percent cellularity).

4. Serum creatinine greater than 2.5mg/dl or serum bilirubin greater than 4mg/dl (patients receiving fludarabine).

5. Co-morbidity of such severity that it would preclude the patient's ability to tolerate protocol therapy.

6. Predicted survival less than 3 months.

7. Previous allergic reaction to Montanide Adjuvant.

8. Pregnant or breast feeding (Pregnant and breast-feeding women are excluded from study because the effects of vaccination are not known and may pose a risk to the developing fetus. All female patients will have a urine pregnancy test, and only those that test negative will be allowed on study).

9. Enrolled in another vaccine clinical trial during the study period.

10. Inability to comprehend the investigational nature of the study and provide informed consent.

Exclusion Criteria-Donor (any of the following):

1. Pregnant or lactating.

2. Unfit to receive filgrastim (G-CSF) and undergo apheresis (abnormal blood counts, history of stroke, uncontrolled hypertension).

3. HIV positive.

4. Severe psychiatric illness. Mental deficiency sufficiently severe as to make compliance with the BMT treatment unlikely and making informed consent impossible.

Special Instructions:

Currently Not Provided

Keywords:

Myelodysplastic Syndrome (MDS)

Acute Myelogenous Leukemia (AML)

Chronic Myelogenous Leukemia (CML)

Acute Lymphoblastic Leukemia (ALL)

Wilm's Tumor-1 Peptide

Recruitment Keyword(s):

Leukemia

Myelodysplastic Syndrome

MDS

Acute Myelogenous Leukemia

AML

Chronic Myelogenous Leukemia

CML

Acute Lymphoblastic Leukemia

ALL

Condition(s):

Myelodysplastic syndrome

Acute Myeloid Leukemia (AML)

Chronic Myeloid Leukemia (CML)

Investigational Drug(s):

WR 1 and PR 1 Peptide Vaccine

Investigational Device(s):

None

Intervention(s):

Drug: WR 1 and PR 1 Peptide Vaccine

Supporting Site:

National Heart, Lung and Blood Institute

Contact(s):

Patient Recruitment and Public Liaison Office
Building 61
10 Cloister Court
Bethesda, Maryland 20892-4754
Toll Free: 1-800-411-1222
TTY: 301-594-9774 (local),1-866-411-1010 (toll free)
Fax: 301-480-9793

Electronic Mail:prpl@mail.cc.nih.gov

Citation(s):

Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2003 Apr 1;101(7):2895-6 Blood. 2002 Oct 1;100(7):2292-30

Hellstrom-Lindberg E, Ahlgren T, Beguin Y, Carlsson M, Carneskog J, Dahl IM, Dybedal I Grimfors G, Kanter-Lewensohn L, Linder O, Luthman M, Lofvenberg E, Nilsson-Ehle H, Samuelsson J, Tangen JM, Winqvist I, Oberg G, Osterborg A, Ost A. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood. 2001 Sep 15;98(6):1985. Blood. 1998 Jul 1;92(1):68-75

Raza A, Meyer P, Dutt D, Zorat F, Lisak L, Nascimben F, du Randt M, Kaspar C, Goldberg C, Loew J, Dar S, Gezer S, Venugopal P, Zeldis J. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood. 2001 Aug 15;98(4):958-65.

• Questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC.
• Technical questions regarding the Clinical Center web site, please contact the Department of Clinical Research Informatics, CC.

Search The Studies | Help | Questions |
Clinical Center Home | NIH Home

National Institutes of Health Clinical Center Bethesda, Maryland 20892. Last update: 01/30/2009